Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 42.97% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 42.97% YoY), while the FY2025 annual figure was $15.8 million, up 103.63% from the prior year.
• Other Non-Current Liabilities came in at $16.1 million for Q1 2026 at Allogene Therapeutics, up from $15.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $16.1 million in Q1 2026 to a low of $5.2 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $7.2 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities soared 156.93% in 2022 and decreased 27.42% in 2023, its largest moves.
• Allogene Therapeutics' Other Non-Current Liabilities stood at $5.8 million in 2022, then retreated by 11.42% to $5.2 million in 2023, then jumped by 49.86% to $7.8 million in 2024, then soared by 103.63% to $15.8 million in 2025, then rose by 2.0% to $16.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $16.1 million, $15.8 million, and $15.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison